Allogene Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 407.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Details
| Name | Allogene Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 152 |
| Founded | 2017 |
| Ipo Date | 2018-10-11 |
| Ceo | Zachary Roberts |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US0197701065 |
| Cusip | 019770106 |
| Cik | 0001737287 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Zachary J. Roberts M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder and Executive Chairman |
| Joshua A. Kazam | Co-Founder and Director |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder and Director |
| Geoffrey M. Parker | Executive Vice President and Chief Financial Officer |
| Annie Yoshiyama | Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer |
| Benjamin M. Beneski | Senior Vice President and Chief Technical Officer |
| Earl M. Douglas Esq. | Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary |
| Susan R. Lundeen | Chief People Officer |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer |
Contact
| Address | 210 East Grand Avenue, South San Francisco, California 94080, United States |
| Phone | 650 457 2700 |
| Website | https://allogene.com |